gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

FDA Approved Opdivo for Metastatic Small-Cell Lung Cancer

October 2018 Vol 4 No 5 – October 17, 2018

In August 2018, the FDA approved the immunotherapy Opdivo (nivolumab; from Bristol-Myers Squibb) for the treatment of patients with metastatic (spreading) small-cell lung cancer that progressed after platinum-based chemotherapy and at least 1 other therapy.

Opdivo was previously approved by the FDA for patients with non–small-cell lung cancer, the most common type of lung cancer. This new approval makes this immunotherapy also available for patients with small-cell lung cancer, which has fewer treatment options.

This approval was based on results from a clinical trial of 109 patients with or without PD-1 expression who had metastatic small-cell lung cancer that progressed after chemotherapy and at least 1 other therapy.

Overall, in 13 patients with small-cell lung cancer, the cancer responded to treatment with Opdivo, and the responses lasted between 6 months to more than 18 months. This new approval for Opdivo now offers patients with small-cell lung cancer access to immunotherapy, an important addition to the treatment options available for patients with this type of lung cancer.

The side effects with Opdivo in this study were similar to those seen in other studies, and 10% of patients discontinued treatment because of side effects.

Recommended For You
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
FDA Approvals, News & UpdatesGastric Cancer
Lonsurf Approved for Metastatic Gastric or Gastroesophageal Junction Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country